On May 31, the "Symposium on the Real-World Study Protocol for Baoji Oral Liquid in the Treatment of Dampness-Turbidity Obstructing the Middle Jiao Syndrome in Research-Oriented Pharmacies" was successfully held in Tianjin. More than 20 participants attended the meeting, including Tang Xudong, Academician (Member of the Academic Division) and Chief Researcher at the China Academy of Chinese Medical Sciences; Professor Zhang Junhua, Vice President of Tianjin University of Traditional Chinese Medicine; Dai Cheng, Vice President of Guangzhou Wanglaoji Pharmaceutical Co., Ltd.; Cheng Mou, Vice President of Minet; and Zhuo Jingxian and Wu Yanmei, Deputy General Managers of Guangzhou Evidence-Based Medicine Technology Co., Ltd.

This meeting leveraged the innovative model of research-oriented pharmacies as its vehicle, aiming to systematically validate the clinical value of Baoji Oral Liquid and clarify its product positioning through a large-scale, multi-center, prospective real-world study. The findings are intended to provide high-quality evidence-based support for Wanglaoji Pharmaceutical's strategy of expanding its "Southern TCM brands to the North," and to elevate this century-old formula into a billion-yuan-level blockbuster TCM product.

Authoritative Leadership: Pioneering a New Scenario for Real-World Research

Professor Zhang Junhua, Vice President of Tianjin University of Traditional Chinese Medicine, stated in his opening remarks that the research paradigm for TCM is shifting from "confirming value" to "discovering value." Research-oriented pharmacies, as a novel decentralized real-world research setting, can closely mirror patients' actual medication environments, precisely identify clinical benefits, and lay a solid foundation for high-quality evidence-based TCM research.

▲Professor Zhang Junhua, Vice President of Tianjin University of TCM, delivering his online address

Cheng Mou, Vice President of Minet, introduced that the model was top-level designed by the Haihe Laboratory, in collaboration with Minet and eight pharmacy chain enterprises, featuring a complete research workflow and a rigorous quality control system—providing a standardized and replicable implementation framework for the Baoji Oral Liquid project.

 ▲Cheng Mou, Vice President of Minet

Focused Protocol Discussion: Expert Precision Guidance, Evidence-Based Full-Process Support

An expert team led by Researcher Tang Xudong, Academician of the China Academy of Chinese Medical Sciences, conducted a comprehensive review of the study protocol, offering critical optimization recommendations on research compliance, efficacy endpoints, patient stratification, and quality control.

▲Tang Xudong, Academician of the China Academy of Chinese Medical Sciences

As a core member of the project team, Guangzhou Evidence-Based Medicine provided on-site responses:

We will fully incorporate the experts' recommendations, refine the study protocol, and supplement supporting documents including Case Report Forms and Investigator's Brochures. We will adopt DCT (Decentralized Clinical Trial) remote trial technologies and an EDC (Electronic Data Capture) system to ensure data standardization, authenticity, and full traceability.

▲Zhuo Jingxian, Deputy General Manager of Guangzhou Evidence-Based Medicine Technology Co., Ltd.

▲ Wu Yanmei, Deputy General Manager of Guangzhou Evidence-Based Medicine Technology Co., Ltd.

This marks the entry of the Baoji Oral Liquid real-world study into a high-quality implementation phase, conducted within a rigorous evidence-based medicine framework and empowered by digital tools.

Supporting the "Southern TCM to the North" Strategy: Driving National Expansion with High-Quality Evidence

Dai Cheng, Vice President of Guangzhou Wanglaoji Pharmaceutical Co., Ltd., noted at the meeting that Baoji Oral Liquid, as a century-old classic formula, has long relied on pharmacies as its primary sales channel in the Guangdong and Guangxi regions—making it a perfect fit for the research-oriented pharmacy model. The company hopes that this study will establish a differentiated product positioning and patient profile, injecting academic momentum into its nationwide commercialization efforts.

▲Dai Cheng, Vice President of Guangzhou Wanglaoji Pharmaceutical Co., Ltd.

The successful convening of this meeting not only consolidated expert consensus and refined the research pathway, but also set an industry benchmark for Chinese patent medicines to conduct real-world studies through research-oriented pharmacies, achieving both academic advancement and market breakthroughs. Guangzhou EBM will continue to leverage its expertise in clinical research design and operational management, working closely with all partners to ensure the project's high-standard implementation. By generating high-quality real-world evidence, we aim to strengthen the product's academic foundation and help this century-old Southern TCM formula benefit more patients across the country.

About Baoji Oral Liquid

Baoji Oral Liquid is an improved dosage form of Baoji Pills and is an exclusive product of Guangzhou Wanglaoji Pharmaceutical Co., Ltd. Its composition includes the following herbs: Guang Huoxiang (Pogostemonis Herba), Baizhi (Angelicae Dahuricae Radix), Cangzhu (Atractylodis Rhizoma), Gouteng (Uncariae Ramulus cum Uncis), Juhua (Chrysanthemi Flos), Jili (Tribuli Fructus), Houpo (Magnoliae Officinalis Cortex), Muxiang (Aucklandiae Radix), Tianhuafen (Trichosanthis Radix), Gegen (Puerariae Lobatae Radix), Hua Juhong (Citri Grandis Exocarpium Rubrum), Yiyiren (Coicis Semen), Daoya (Oryzae Fructus Germinatus), Bohe (Menthae Haplocalycis Herba), Fuling (Poria), and Guangdong Shenqu (Massa Medicata Fermentata). It has the effects of relieving exterior syndromes, dispelling dampness, and harmonizing the middle jiao (spleen and stomach).

▲ Wanglaoji Baoji Oral Liquid